Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2017

Open Access 01-12-2017 | Research

Curcumin suppresses gastric tumor cell growth via ROS-mediated DNA polymerase γ depletion disrupting cellular bioenergetics

Authors: Lihua Wang, Xiwen Chen, Zhuanyun Du, Gefei Li, Mayun Chen, Xi Chen, Guang Liang, Tongke Chen

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2017

Login to get access

Abstract

Background

Curcumin, as a pro-apoptotic agent, is extensively studied to inhibit tumor cell growth of various tumor types. Previous work has demonstrated that curcumin inhibits cancer cell growth by targeting multiple signaling transduction and cellular processes. However, the role of curcumin in regulating cellular bioenergetic processes remains largely unknown.

Methods

Western blotting and qRT-PCR were performed to analyze the protein and mRNA level of indicated molecules, respectively. RTCA, CCK-8 assay, nude mice xenograft assay, and in vivo bioluminescence imaging were used to visualize the effects of curcmin on gastric cancer cell growth in vitro and in vivo. Seahorse bioenergetics analyzer was used to investigate the alteration of oxygen consumption and aerobic glycolysis rate.

Results

Curcumin significantly inhibited gastric tumor cell growth, proliferation and colony formation. We further investigated the role of curcumin in regulating cellular redox homeostasis and demonstrated that curcumin initiated severe cellular apoptosis via disrupting mitochondrial homeostasis, thereby enhancing cellular oxidative stress in gastric cancer cells. Furthermore, curcumin dramatically decreased mtDNA content and DNA polymerase γ (POLG) which contributed to reduced mitochondrial oxygen consumption and aerobic glycolysis. We found that curcumin induced POLG depletion via ROS generation, and POLG knockdown also reduced oxidative phosphorylation (OXPHOS) activity and cellular glycolytic rate which was partially rescued by ROS scavenger NAC, indiating POLG plays an important role in the treatment of gastric cancer. Data in the nude mice model verified that curcumin treatment significantly attenuated tumor growth in vivo. Finally, POLG was up-regulated in human gastric cancer tissues and primary gastric cancer cell growth was notably suppressed due to POLG deficiency.

Conclusions

Together, our data suggest a novel mechanism by which curcumin inhibited gastric tumor growth through excessive ROS generation, resulting in depletion of POLG and mtDNA, and the subsequent disruption of cellular bioenergetics.
Literature
1.
2.
Mullen JT, Ryan DP. Neoadjuvant chemotherapy for gastric cancer: what are we trying to accomplish? Ann Surg Oncol. 2014;21(1):13–5.CrossRefPubMed
3.
Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;3:CD004064.
4.
Graziano F, Catalano V, Lorenzini P, Giacomini E, Sarti D, Fiorentini G, De Nictolis M, Magnani M, Ruzzo A. Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy. Pharmacogenomics J. 2014;14(5):418–23.CrossRefPubMed
5.
Huang MT. Antioxidant and antitumorgenic properties of curcumin. In: Ohigashi H, Osawa T, Terao S, Watanabe S, Yoshikawa T, editors. Food Factors for Cancer Prevention. Tokyo: Springer; 1997. p. 249–52.CrossRef
6.
Joe B, Vijaykumar M, Lokesh BR. Biological properties ofcurcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr. 2004;44:97–111.CrossRefPubMed
7.
Aggarwal BB, Kumar A, Bharti AC. Anticancer potentialof curcumin: Preclinical and clinical studies. Anticancer Res. 2003;23:363–98.PubMed
8.
9.
Leu TH, Maa MC. The molecular mechanisms for theantitumorigenic effect of curcumin. Curr Med Chem Anticancer Agents. 2002;2:357–70.CrossRefPubMed
10.
Chauhan DP. Chemotherapeutic potential of curcumin forcolorectal cancer. Curr Pharm Des. 2002;8:1695–706.CrossRefPubMed
11.
12.
Karunagaran D, Rashmi R, Kumar TR. Induction ofapoptosis by curcumin and its implications for cancer therapy. Curr Cancer Drug Targets. 2005;5:117–29.CrossRefPubMed
13.
Duvoix A, Blasius R, Delhalle S, Schnekenburger M. et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 2005;223:181–90.
14.
Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: A short review. Life Sci. 2006;78:2081–7.CrossRefPubMed
15.
Thomasset SC, Berry DP, Garcea G, Marczylo T, et al. Dietary polyphenolic phytochemicals-promising cancerchemopreventive agents in humans? A reviewof their clinicalproperties. Int J Cancer. 2007;120:451–8.CrossRefPubMed
16.
17.
Singh S, Khar A. Biological effects of curcumin and itsrole in cancer chemoprevention and therapy. Anticancer Agents Med Chem. 2006;6:259–70.CrossRefPubMed
18.
Aggarwal BB, Shishodia S. Molecular targets of dietaryagents for prevention and therapy of cancer. Biochem Pharmacol. 2006;71:1397–421.CrossRefPubMed
19.
Johnson JJ, Mukhtar H. Curcumin for chemoprevention ofcolon cancer. Cancer Lett. 2007;255:170–81.CrossRefPubMed
20.
Shishodia S, Chaturvedi MM, Aggarwal BB. Role ofcurcumin in cancer therapy. Curr Probl Cancer. 2007;31:243–305.CrossRefPubMed
21.
Marcu MG, Jung YJ, Lee S, et al. Curcumin is an inhibitor ofp300 histone acetylatransferase. Med Chem. 2006;2:169–74.CrossRefPubMed
22.
Hu J, Wang Y, Chen Y. Curcumin-induced histone acetylationin malignant hematologic cells. J Huazhong Univ Sci Technolog Med Sci. 2009;29:25–8.CrossRefPubMed
23.
Morin D, Barthelemy S, Zini R, Labidalle S, Tillement JP. Curcumin induces the mitochondrial permeability transitionpore mediated by membrane protein thiol oxidation. FEBS Lett. 2001;495:131–6.CrossRefPubMed
24.
Bentzen PJ, Lang E, Lang F. Curcumin induced suicidalerythrocyte death. Cell Physiol Biochem. 2007;19:153–64.CrossRefPubMed
25.
Bae JH, Park JW, Kwon TK. Ruthenium red, inhibitor ofmitochondrial Ca2+ uniporter, inhibits curcumin-induced apoptosisvia the prevention of intracellular Ca2+ depletion andcytochrome c release. Biochem Biophys Res Commun. 2003;303:1073–9.CrossRefPubMed
26.
Kuttan G, Kumar KB, Guruvayoorappan C, Kuttan R. Antitumor,anti-invasion, and antimetastatic effects of curcumin. Adv Exp Med Biol. 2007;595:173–84.CrossRefPubMed
27.
Aggarwal S, Ichikawa H, Takada Y, Sandur SK, ShishodiaS ABB. Curcumin (diferuloylmethane) down-regulatesexpression of cell proliferation and antiapoptotic andmetastatic gene products through suppression of IkappaBalphakinase and Akt activation. Mol Pharmacol. 2006;69:195–206.PubMed
28.
Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D’Alessandro N. Antitumor effects of curcumin, alone or incombination with cisplatin or doxorubicin, on human hepaticcancer cells. Analysis of their possible relationship to changes inNF-kB activation levels and in IAP gene expression. Cancer Lett. 2005;224:53–65.CrossRefPubMed
29.
Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-kappaB and IkappaB kinase are constitutivelyactive in human pancreatic cells, and their down-regulation bycurcumin (diferuloylmethane) is associated with the suppressionof proliferation and the induction of apoptosis. Cancer. 2004;101:2351–62.CrossRefPubMed
30.
Jeong WS, Kim IW, Hu R, Kong AN. Modulation ofAP-1 by natural chemopreventive compounds in humancolon HT-29 cancer cell line. Pharm Res. 2004;21:649–60.CrossRefPubMed
31.
Bortel N, Armeanu-Ebinger S, Schmid E, Kirchner B, et al. Effects of curcumin in pediatric epithelial liver tumors: inhibition of tumor growth and alpha-fetoprotein in vitro and in vivo involving the NFkappaB- and the beta-catenin pathways. Oncotarget. 2015;6(38):40680–91.PubMedPubMedCentral
32.
Yang X, Lv JN, Li H, Jiao B, et al. Curcumin reduces lung inflammation via Wnt/β-catenin signaling in mouse model of asthma. J Asthma. 2016;15:1–6.CrossRef
33.
Zhang X, Wu J, Ye B, Wang Q, Xie X, Shen H. Protective effect of curcumin on TNBS-induced intestinal inflammation is mediated through the JAK/STAT pathway. BMC Complement Altern Med. 2016;20(16(1)):299.CrossRef
34.
Hu A, Huang JJ, Jin XJ, et al. Curcumin suppresses invasiveness and vasculogenic mimicry of squamous cell carcinoma of the larynx through the inhibition of JAK-2/STAT-3 signaling pathway. Am J Cancer Res. 2014;15(5(1)):278–88.
35.
Liu LB, Duan CN, Ma ZY, Xu G. Curcumin inhibited rat colorectal carcinogenesis by activating PPAR-γ: an experimental study. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015;35(4):471–5.PubMed
36.
Chen A, Xu J. Activation of PPAR{gamma} bycurcumin inhibits Moser cell growth and mediates suppressionof gene expression of cyclin D1 and EGFR. Am J Physiol. 2005;288:G447–56.
37.
Kumar D, Basu S, Parija L, Rout D, et al. Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells. Biomed Pharmacother. 2016;81:31–7.CrossRefPubMed
38.
Chen J, Li L, Su J, Li B, Zhang X, Chen T. Proteomic Analysis of G2/M Arrest Triggered by Natural Borneol/Curcumin in HepG2 Cells, the Importance of the Reactive Oxygen Species-p53 Pathway. J Agric Food Chem. 2015;22(63(28)):6440–9.CrossRef
39.
Xi Y, Gao H, Callaghan MU, et al. Induction of BCL2-Interacting Killer, BIK, is Mediated for Anti-Cancer Activity of Curcumin in Human Head and Neck Squamous Cell Carcinoma Cells. J Cancer. 2015;6(4):327–32.CrossRefPubMedPubMedCentral
40.
Singh S, Aggarwal BB. Activation of transcriptionfactor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem. 1995;270:24995–5000.CrossRefPubMed
41.
Shishodia S, Amin HM, Lai R, et al. Curcumin (diferuloylmethane)inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and inducesapoptosis in mantle cell lymphoma. Biochem Pharmacol. 2005;70:700–13.CrossRefPubMed
42.
Han SS, Chung ST, Robertson DA, et al. Curcumincauses the growth arrest and apoptosis of B cell lymphomaby downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol. 1999;93:152–61.CrossRefPubMed
43.
Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumininvolves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene. 1999;18(44):6013–20.
44.
Tong W, Wang Q, Sun D, Suo J. Curcumin suppresses colon cancer cell invasion via AMPK-induced inhibition of NF-κB, uPA activator and MMP9. Oncol Lett. 2016;12(5):4139–46.PubMedPubMedCentral
45.
Li G, Bu J, Zhu Y, et al. Curcumin improves bone microarchitecture in glucocorticoid-induced secondary osteoporosis mice through the activation of microRNA-365 via regulating MMP-9. Int J Clin Exp Pathol. 2015;8(12):15684–95.PubMedPubMedCentral
46.
Hussain AR, Al-Rasheed M, Manogaran PS, et al. Curcumin induces apoptosis via inhibition of PI30-kinase/AKT pathway in acute T cell leukemias. Apoptosis. 2006;11:245–54.CrossRefPubMed
47.
Lim W, Jeong M, Bazer FW, Song G. Curcumin Suppresses Proliferation and Migration and Induces Apoptosis on Human Placental Choriocarcinoma Cells via ERK1/2 and SAPK/JNK MAPK Signaling Pathways. Biol Reprod. 2016. Epub ahead of print.
48.
Shang W, Zhao LJ, Dong XL, et al. Curcumin inhibits osteoclastogenic potential in PBMCs from rheumatoid arthritis patients via the suppression of MAPK/RANK/c-Fos/NFATc1 signaling pathways. Mol Med Rep. 2016;14(4):3620–6.PubMedPubMedCentral
49.
Fetoni AR, Paciello F, Mezzogori D. Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role ofcurcumin on pSTAT3 and Nrf-2 signalling. Br J Cancer. 2015;113(10):1434–44.CrossRefPubMedPubMedCentral
50.
Bibb MJ, Van Etten RA, Wright CT, et al. Sequence and gene organization of mouse mitochondrial DNA. Cell. 1981;26(2 Pt 2):167–80.CrossRefPubMed
51.
Warburg O, Wind F, Negelein E. The metabolism of tumors inthe body. J Gen Phys. 1927;8(6):519–30.CrossRef
52.
53.
Antico L, Zecchi P. Relations between metabolism and cardiac function. IV. Effect of inhibitors of glycolysis, 2-deoxyglucose and iodoacetate, on the electrocardiogram and on the dynamics of the isolated heart. Chir Patol Sper. 1968;6(Suppl 6):85–91.
54.
55.
Xie C, Jin J, Bao X, et al. Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer. Oncotarget. 2016;7(1):610–21.PubMed
56.
Wu Y, Qi Y, Liu H, et al. AMPK activator AICAR promotes 5-FU-induced apoptosis in gastric cancer cells. Mol Cell Biochem. 2016;411(1-2):299–305.CrossRefPubMed
57.
Gollavilli PN, Kanugula AK, Koyyada R, et al. AMPK inhibits MTDH expression via GSK3β and SIRT1 activation: potential role in triple negative breast cancer cell proliferation. FEBS J. 2015;282(20):3971–85.CrossRefPubMed
58.
Thayyullathil F, Rahman A, Pallichankandy S, Patel M, Galadari S. ROS-dependent prostate apoptosis response-4 (Par-4) up-regulation and ceramide generation are the prime signaling events associated with curcumin-induced autophagic cell death in human malignant glioma. FEBS Open Bio. 2014;4:763–76.CrossRefPubMedPubMedCentral
59.
Thayyullathil F, Chathoth S, Hago A, Patel M, Galadari S. Rapid reactive oxygen species (ROS) generation induced by curcumin leads to caspase-dependent and -independent apoptosis in L929 cells. Free Radic Biol Med. 2008;45(10):1403–12.CrossRefPubMed
60.
Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by thesword. Cancer Cell. 2006;10:175–6.CrossRefPubMed
61.
62.
Deisenroth C, Franklin DA, Zhang Y. The Evolution of the Ribosomal Protein-MDM2-p53 Pathway. Cold Spring Harb Perspect Med. 2016;6(12):1–15.
63.
Pant V, Xiong S, Chau G, Tsai K, Shetty G, Lozano G. Distinct downstream targets manifest p53-dependent pathologies in mice. Oncogene. 2016;35(44):5713–21.CrossRefPubMedPubMedCentral
64.
Karabay AZ, Koc A, Ozkan T, et al. Methylsulfonylmethane Induces p53 Independent Apoptosis in HCT-116 Colon Cancer Cells. Int J Mol Sci. 2016;15:17(7).
65.
Lee WT, Chang CW. Bax is upregulated by p53 signal pathway in the SPE B-induced apoptosis. Mol Cell Biochem. 2010;343(1-2):271–9.CrossRefPubMed
66.
Le Pen J, Laurent M, Sarosiek K, et al. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL. Cell Death Dis. 2016;4(7):e2083. doi:10.​1038/​cddis.​2015.​400.CrossRef
67.
Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126:107–20.CrossRefPubMed
Metadata
Title
Curcumin suppresses gastric tumor cell growth via ROS-mediated DNA polymerase γ depletion disrupting cellular bioenergetics
Authors
Lihua Wang
Xiwen Chen
Zhuanyun Du
Gefei Li
Mayun Chen
Xi Chen
Guang Liang
Tongke Chen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2017
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-017-0513-5

Other articles of this Issue 1/2017

Journal of Experimental & Clinical Cancer Research 1/2017 Go to the issue

Research

Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice

Research

PIG3 promotes NSCLC cell mitotic progression and is associated with poor prognosis of NSCLC patients

Research

LPS alters the immuno-phenotype of glioma and glioma stem-like cells and induces in vivo antitumor immunity via TLR4

Research

Doxorubicin combined with low intensity ultrasound suppresses the growth of oral squamous cell carcinoma in culture and in xenografts

Research

Sophoridine induces apoptosis and S phase arrest via ROS-dependent JNK and ERK activation in human pancreatic cancer cells

Research

Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits